Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BZ 371A

Next Previous
Drug Profile

BZ 371A

Alternative Names: BZ-371A; PnPP-19

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Biozeus
  • Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Neuroprotectants; Peptides
  • Mechanism of Action Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic nerve disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Erectile dysfunction; Female sexual dysfunction
  • Preclinical Diabetic retinopathy; Dry age-related macular degeneration; Glaucoma; Lung disorders; Optic nerve disorders
  • No development reported Eye disorders

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for preclinical development in Eye-disorders in Brazil (Ophthalmic)
  • 23 Oct 2024 Biozeus Biopharmaceutical plans a phase II trial for Female sexual dysfunction in Brazil (Topical, Gel) in July 2025 (NCT06651541)
  • 01 Oct 2024 Phase-II clinical trials in Female sexual dysfunction in Brazil (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top